Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
146 Results for "
Stat 5
" in MedChemExpress (MCE) Product Catalog:
Products (146)
146 Results for "Stat 5" in MCE Product Catalog:
Cat. No.: HY-148748G
CAS No.: 1110767-45-7
Cat. No.: HY-107429R
CAS No.: 1622902-68-4
Synonyms: PF-04965842 (Standard)
Target:
Research Areas:
Abrocitinib (Standard) is the analytical standard of Abrocitinib. This product is intended for research and analytical applications. Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease .
Cat. No.: HY-RS13893
Target:
Research Areas:
STAT5B Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-170837
STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer activity. STAT5-IN-3 blocks the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites and significantly reduces the expression of STAT5B protein, thereby inhibiting downstream gene transcription and blocking the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 holds significant value in overcoming chemotherapy resistance .
Cat. No.: HY-40354AS
CAS No.: 2701680-77-3
Synonyms: Tasocitinib-d3 citrate; CP-690550-d3 citrate
Target:
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
Tofacitinib-d3 citrate (Tasocitinib-d3 citrate; CP-690550-d3 citrate) is the deuterated-labeled Tofacitinib citrate (HY-40354A). Tofacitinib citrate (Tasocitinib citrate) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib citrate blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib citrate can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .
Cat. No.: HY-40354S1
Synonyms: Tasocitinib-13C3,15N; CP-690550-13C3,15N
Target:
Tofacitinib- 13C3, 15N (Tasocitinib- 13C3, 15N; CP-690550- 13C3, 15N) is the 15N, 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury .
Cat. No.: HY-155746
CAS No.: 2568842-26-0
JAK2-IN-9 is an orally active selective JAK2 inhibitor with a human IC50 of 5 nM. JAK2-IN-9 inhibits JAK2 kinase activity, blocks JAK2 phosphorylation, and suppresses the activation of the downstream JAK2-STAT signaling pathway. JAK2-IN-9 inhibits the phosphorylation of STAT3, STAT5 and AKT in cancer cells. JAK2-IN-9 induces cancer cell apoptosis (apoptosis) and cell cycle arrest. JAK2-IN-9 can be used for the research of myeloproliferative neoplasms .
Cat. No.: HY-125151
CAS No.: 1334492-85-1
BP-1-108 is a selective inhibitor of STAT5 (Ki=8.3 μM) with anticancer activity. BP-1-108 induces apoptosis of leukemia cells by inhibiting the phosphorylation of STAT5. BP-1-108 can be used in the study of acute myeloid leukemia and prostate cancer .
Cat. No.: HY-120457
CAS No.: 1141855-86-8
Research Areas:
WYE-151650 is a selective JAK-3 inhibitor. WYE-151650 suppresses IL-2-induced STAT-5 phosphorylation and cell proliferation mediated by JAK-3. WYE-151650 is promising for research of autoimmune diseases .
Synonyms: R6238-d4
Cat. No.: HY-12987S1
CAS No.: 1794795-40-6
Cat. No.: HY-174988
JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .
Cat. No.: HY-175273
MA191 is a FLT3 PROTAC degrader. MA191 targets and degrades mutant FLT3-ITD protein by recruiting the VHL E3 ligase in a manner dependent on ubiquitination and BIM, thereby blocking aberrant downstream MAPK/STAT5 signaling pathways and inducing apoptosis. MA191 can be used in research related to acute myeloid leukemia .
Target:
Research Areas:
JAK-IN-24 is a JAK inhibitor, with IC50s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 also inhibits PBMC IL-15 induced STAT5 phosphorylation with an IC50 of 86.171 nM . JAK-IN-24 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-120604
CAS No.: 1414587-22-6
Synonyms: NVP_BVB808
BVB808 (NVP_BVB808) is a selective JAK2 inhibitor with approximately 10-fold selectivity for JAK2 over other JAK family members (such as JAK1, JAK3 or TYK2) in vitro. BVB808 inhibits the activity of JAK2 and reduces the phosphorylation of STAT5, thereby blocking the JAK2-dependent cell proliferation and survival signaling pathways. BVB808 can be used in cancer research .
Cat. No.: HY-RS13892
Target:
Research Areas:
STAT5A Human Pre-designed siRNA Set A contains three designed siRNAs for STAT5A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS13894
Target:
Research Areas:
Stat5b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS13895
Target:
Research Areas:
Stat5b Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat5b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-101853R
CAS No.: 285986-31-4
Target:
Research Areas:
STAT5-IN-1 (Standard) is the analytical standard of STAT5-IN-1 (HY-101853). This product is intended for research and analytical applications. STAT5-IN-1 is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.
Cat. No.: HY-102048R
CAS No.: 2111834-61-6
Target:
Research Areas:
STAT5-IN-2 (Standard) is the analytical standard of STAT5-IN-2 (HY-102048). This product is intended for research and analytical applications. STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
